Cargando…
California Cardiovascular Screening Tool: Findings from Initial Implementation
Objective American College of Obstetricians and Gynecologists (ACOG) recently published the California (CA) cardiovascular disease (CVD) screening algorithm for pregnant and postpartum women. We aim to prospectively determine screen-positive and true-positive rates of CVD among women across two pop...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Thieme Medical Publishers, Inc.
2020
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7669431/ https://www.ncbi.nlm.nih.gov/pubmed/33214931 http://dx.doi.org/10.1055/s-0040-1718382 |
_version_ | 1783610568981086208 |
---|---|
author | Blumenthal, Elizabeth A. Crosland, B. Adam Senderoff, Dana Santurino, Kathryn Garg, Nisha Bernstein, Megan Wolfe, Diana Hameed, Afshan |
author_facet | Blumenthal, Elizabeth A. Crosland, B. Adam Senderoff, Dana Santurino, Kathryn Garg, Nisha Bernstein, Megan Wolfe, Diana Hameed, Afshan |
author_sort | Blumenthal, Elizabeth A. |
collection | PubMed |
description | Objective American College of Obstetricians and Gynecologists (ACOG) recently published the California (CA) cardiovascular disease (CVD) screening algorithm for pregnant and postpartum women. We aim to prospectively determine screen-positive and true-positive rates of CVD among women across two populations. Study Design This is a prospective cohort study of obstetrical patients from April 2018 to July 2019 at academic medical centers in CA and New York (NY). We attempted to screen all patients at least once during their pregnancy care (prenatal or postpartum). Women who screened positive (“Red Flags,” >3–4 moderate risk factors, abnormal physical examination, and persistent symptoms) underwent further testing. The primary outcome was the screen-positive rate. Secondary outcomes included the true-positive rate and the strength of each moderate factor in predicting a positive CVD screen. Results We screened 846 women. The overall screen-positive rate was 8% (5% in CA vs. 19% in NY). The sites differed in ethnicity, that is, African American women (2.7% in CA vs. 35% in NY, p < 0.01) and substance use (2.7 vs. 5.6%, p < 0.04). The true-positive rate was 1.5% at both sites. The percentage of screen-positive patients who did not complete follow-up studies was higher in NY (70%) than in CA (27%). CVD was confirmed in 30% with positive screens with complete follow-up. Combinations of moderate factors were the main driver of screen-positive rates in both populations. Conclusion This is the first data describing the performance of the CVD screening algorithm in a general obstetric population. Factors, such as proportion of African American women affect the likelihood of a positive screen. The screening algorithm highlights patients at higher lifetime risk of CVD and may identify a group that could be targeted for more direct care transitions postpartum. Data may be used to design a larger validation study. |
format | Online Article Text |
id | pubmed-7669431 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Thieme Medical Publishers, Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-76694312020-11-18 California Cardiovascular Screening Tool: Findings from Initial Implementation Blumenthal, Elizabeth A. Crosland, B. Adam Senderoff, Dana Santurino, Kathryn Garg, Nisha Bernstein, Megan Wolfe, Diana Hameed, Afshan AJP Rep Objective American College of Obstetricians and Gynecologists (ACOG) recently published the California (CA) cardiovascular disease (CVD) screening algorithm for pregnant and postpartum women. We aim to prospectively determine screen-positive and true-positive rates of CVD among women across two populations. Study Design This is a prospective cohort study of obstetrical patients from April 2018 to July 2019 at academic medical centers in CA and New York (NY). We attempted to screen all patients at least once during their pregnancy care (prenatal or postpartum). Women who screened positive (“Red Flags,” >3–4 moderate risk factors, abnormal physical examination, and persistent symptoms) underwent further testing. The primary outcome was the screen-positive rate. Secondary outcomes included the true-positive rate and the strength of each moderate factor in predicting a positive CVD screen. Results We screened 846 women. The overall screen-positive rate was 8% (5% in CA vs. 19% in NY). The sites differed in ethnicity, that is, African American women (2.7% in CA vs. 35% in NY, p < 0.01) and substance use (2.7 vs. 5.6%, p < 0.04). The true-positive rate was 1.5% at both sites. The percentage of screen-positive patients who did not complete follow-up studies was higher in NY (70%) than in CA (27%). CVD was confirmed in 30% with positive screens with complete follow-up. Combinations of moderate factors were the main driver of screen-positive rates in both populations. Conclusion This is the first data describing the performance of the CVD screening algorithm in a general obstetric population. Factors, such as proportion of African American women affect the likelihood of a positive screen. The screening algorithm highlights patients at higher lifetime risk of CVD and may identify a group that could be targeted for more direct care transitions postpartum. Data may be used to design a larger validation study. Thieme Medical Publishers, Inc. 2020-10 2020-11-16 /pmc/articles/PMC7669431/ /pubmed/33214931 http://dx.doi.org/10.1055/s-0040-1718382 Text en The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. ( https://creativecommons.org/licenses/by-nc-nd/4.0/ ) https://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License, which permits unrestricted reproduction and distribution, for non-commercial purposes only; and use and reproduction, but not distribution, of adapted material for non-commercial purposes only, provided the original work is properly cited. |
spellingShingle | Blumenthal, Elizabeth A. Crosland, B. Adam Senderoff, Dana Santurino, Kathryn Garg, Nisha Bernstein, Megan Wolfe, Diana Hameed, Afshan California Cardiovascular Screening Tool: Findings from Initial Implementation |
title | California Cardiovascular Screening Tool: Findings from Initial Implementation |
title_full | California Cardiovascular Screening Tool: Findings from Initial Implementation |
title_fullStr | California Cardiovascular Screening Tool: Findings from Initial Implementation |
title_full_unstemmed | California Cardiovascular Screening Tool: Findings from Initial Implementation |
title_short | California Cardiovascular Screening Tool: Findings from Initial Implementation |
title_sort | california cardiovascular screening tool: findings from initial implementation |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7669431/ https://www.ncbi.nlm.nih.gov/pubmed/33214931 http://dx.doi.org/10.1055/s-0040-1718382 |
work_keys_str_mv | AT blumenthalelizabetha californiacardiovascularscreeningtoolfindingsfrominitialimplementation AT croslandbadam californiacardiovascularscreeningtoolfindingsfrominitialimplementation AT senderoffdana californiacardiovascularscreeningtoolfindingsfrominitialimplementation AT santurinokathryn californiacardiovascularscreeningtoolfindingsfrominitialimplementation AT gargnisha californiacardiovascularscreeningtoolfindingsfrominitialimplementation AT bernsteinmegan californiacardiovascularscreeningtoolfindingsfrominitialimplementation AT wolfediana californiacardiovascularscreeningtoolfindingsfrominitialimplementation AT hameedafshan californiacardiovascularscreeningtoolfindingsfrominitialimplementation |